Drug Trial Radar · NCT01732770
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
643
Actual
Start
Nov 7, 2012
Primary completion
Jan 7, 2015
Study completion Jan 7, 2015
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
Conditions
- Post Menopausal Osteoporosis
Interventions
DenosumabBiological
Denosumab 60 mg administered by subcutaneous injection once every 6 months.
Zoledronic AcidDrug
Zoledronic acid 5 mg administered by intravenous infusion once a year
Placebo to DenosumabDrug
Administered by subcutaneous injection once every 6 months
Placebo to Zoledronic AcidDrug
Administered by intravenous infusion once a year
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority AnalysisTime frame: Baseline and Month 12
Locations
45 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Santa Monica, California
Research Site
Lakewood, Colorado
Research Site
Longmont, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Bethesda, Maryland
Research Site
Hagerstown, Maryland
Research Site
Detroit, Michigan
Research Site
West Haverstraw, New York
Research Site
Houston, Texas
Research Site
Maroubra, New South Wales, Australia
Research Site
Penrith, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Geelong, Victoria, Australia
Research Site
Parkville, Victoria, Australia
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Genk, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Merksem, Belgium
Research Site
Tessenderlo, Belgium
Research Site
Wilrijk, Belgium
Research Site
Yvoir, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Aalborg, Denmark
Research Site
Ballerup Municipality, Denmark
Research Site
Vejle, Denmark
Research Site
Bialystok, Poland
Research Site
Krakow, Poland
Research Site
Torun, Poland
Research Site
Warsaw, Poland
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.